Results 181 to 190 of about 41,988 (241)

Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.

Journal of Clinical Oncology, 2019
2505 Background: CPI-006 inhibits CD73, a nucelotidase that converts AMP to adenosine and functions as a lymphocyte adhesion molecule. CPI-006 is a humanized IgG1 FcγR binding-deficient antibody that binds to CD73+ T and B lymphocytes leading to ...
J. Luke, J. Powderly, J. Merchan, M. Barve, A. Hotson, M. Mobasher, L. Kwei, G. Luciano, J. Buggy, E. Piccione, Richard A. Miller   +10 more
semanticscholar   +1 more source

A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.

Journal of Clinical Oncology, 2019
2641 Background: ECI-006 is a combination of TriMix (mRNAs encoding for dendritic cell [DC] activating molecules [CD40L, CD70 and caTLR4]), and mRNAs encoding for melanoma-specific tumor-associated antigens (TAAs): tyrosinase, gp100, MAGE-A3, MAGE-C2 ...
Ana Maria Arance Fernandez, J. Baurain, C. Vulsteke, A. Rutten, A. Soria, J. Carrasco, B. Neyns, B. Keersmaecker, T. Assche, B. Lindmark   +9 more
semanticscholar   +1 more source

Novel neuroprotective tetramethylpyrazine analog T-006 promotes neurogenesis and neurological restoration in a rat model of stroke

NeuroReport, 2019
Neuronal death is among the deleterious pathological changes that occur after cerebral ischemia and can lead to transient or permanent neurological deficits.
Liangmiao Wu, Jie Cao, Ning Li, Haiyun Chen, Wei Liu, Gao-xiao Zhang, Yu Liu, Yuqiang Wang, Yewei Sun, Zaijun Zhang   +9 more
semanticscholar   +1 more source

O-006

Epidemiology, 2012
Yueh-Hsiu Mathilda Chiu, Robert O. Wright, Alexandros Gryparis, Brent Coull, Rosalind J. Wright   +4 more
openaire   +1 more source

The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer’s Disease

Journal of Molecular Neuroscience, 2021
Guiliang Zhang, Jiahui Wu, Chunhui Huang, Jiehong Cheng, Zhiyang Su, Zeyu Zhu, Xifei Yang, Baojian Guo, Liangmiao Wu, Zaijun Zhang, Gao-xiao Zhang, Haiyun Chen, Yewei Sun, Yuqiang Wang   +13 more
semanticscholar   +1 more source

E-006

Epidemiology, 2012
Laura Zheng, Jason Umans, Maria Tellez-Plaza, Barbara Howard, Fawn Yeh, Kevin Francesconi, Walter Goessler, Ellen Silbergeld, Eliseo Guallar, Virginia Weaver, Ana Navas-Acien   +10 more
openaire   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

The Lancet, 2017
J. Schachter, A. Ribas, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Honghong Zhou, S. Ebbinghaus, N. Ibrahim, C. Robert   +19 more
semanticscholar   +1 more source

P-006

Epidemiology, 2012
Ji-Young Lee, Jong-Han Leem, Eun-Hee Ha, Kim Hwan-Cheol, Myung-Sook Park, Dal-Young Chung, Kim Jung-Ae, Kweon Jung, Nam-Jin Kim, Hyesook Park, Mina Ha, Yangho Kim, Seung-Do Yu, Chulwoo Lee   +13 more
openaire   +1 more source

Bronx Project-006-A, (BP-006-A)

2022
openaire   +1 more source

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

, 2018
G. Long, J. Schachter, A. Ribas, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, James R. Anderson, C. Krepler, N. Ibrahim, C. Robert   +19 more
semanticscholar   +1 more source